Zymeworks Inc. (ZYME): R&D Expense
$137.00M
Year ended 2025-12-31
$128.71M
Trailing 12 months to 2026-06-30
-13.1%
3-year compound annual growth
-4.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $137.00M | +1.8% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $134.62M | -6.3% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $143.62M | -31.1% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $208.60M | +4.4% | 2025-03-05, From 2022-01-01 |
| 2021-12-31 | $199.75M | +16.7% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $171.20M | n/a | 2023-03-07, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Zymeworks Inc. (ZYME) | 2025-12-31 | $137.00M | +1.8% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $12.74M | -69.7% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $37.41M | -0.6% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $67.11M | +17.4% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $19.96M | +62.1% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.43M | +5.2% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $416.03M | +22.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
Compare ZYME, ZVRA, TBPH, URGN side by side · Screen every company in Pharmaceutical Preparations ↗